The global rapid influenza diagnostic tests (RIDTs) industry is witnessing accelerated growth driven by increasing demand for timely influenza detection and improved healthcare infrastructure worldwide. The market’s evolution reflects rising awareness of influenza management, along with technological advancements enhancing test accuracy and speed, making it pivotal for public health and clinical settings.
Market Size and Overview
The rapid influenza diagnostic tests market size is expected to reach US$ 2.60 Bn by 2032, from US$ 1.51 Bn in 2025, at a CAGR of 8.1% during the forecast period.
This growth underscores the expanding Global Rapid Influenza Diagnostic Tests Market revenue and significant business growth opportunities in influenza diagnostics. Increasing emphasis on early disease detection and rising influenza prevalence during seasonal outbreaks are key factors contributing to the favorable market forecast. The market report also highlights ongoing innovation aimed at improving test sensitivity and reducing turnaround times.
Market Segments
This market can be broadly segmented into product type, end user, and technology. Under product type, lateral flow immunoassays remain the dominant sub-segment, accounting for a substantial portion of market revenue in 2024 due to their portability and ease of use in point-of-care settings. The fastest-growing segment is molecular rapid influenza diagnostic tests, with adoption surging 12% in 2025, attributed to their higher accuracy and ability to differentiate influenza subtypes. The end-user segment includes hospitals, clinics, and diagnostic laboratories, where hospitals dominate, given their high test volumes. Among technology types, nucleic acid amplification tests (NAAT) have shown fastest growth due to improved sensitivity and specificity demonstrated in 2024 clinical deployments.
Market Drivers
A key market driver is the increasing adoption of rapid testing facilitated by supportive health policies and government funding aimed at influenza surveillance and outbreak control. For example, in 2024, several national healthcare agencies invested in expanding RIDT availability across community clinics, leading to a 15% rise in test uptake. Additionally, innovations such as multiplex testing, which can diagnose influenza alongside other respiratory pathogens, enhanced market scope and business growth potential. This synergy between technology advancement and policy support is instrumental in driving market trends and overall market growth.
Segment Analysis: Product Type
Within the product type segment, lateral flow assays are dominant due to their affordability and quick results, generating the highest market revenue in 2024 with over USD 700 million globally. However, molecular RIDTs outperform in growth rate, expanding at 11.8% CAGR through 2025, fueled by rising demand for higher diagnostic accuracy. For instance, a 2025 study published by a leading healthcare system demonstrated molecular RIDTs’ effectiveness in reducing influenza misdiagnoses by 25%, which catalyzed increased adoption within diagnostic laboratories. This segment analysis highlights important market dynamics that experts should consider when evaluating investment or strategic initiatives.
Consumer Behaviour Insights
From 2024 to 2025, several behavioral shifts emerged among end users. Firstly, there is heightened preference for rapid, easy-to-use diagnostics in outpatient settings, driven by patient demand for convenience and minimal wait times. Secondly, a growing segment of consumers shows increased awareness and willingness to pay a premium for multiplex and molecular RIDTs, emphasizing quality and precision over cost sensitivity. Lastly, sustainability considerations began influencing procurement decisions, with hospitals in North America and Europe integrating eco-friendly packaging and reducing plastic usage in test kits, responding to broader healthcare sustainability trends documented in recent feedback reports.
Key Players
Leading companies contributing to the Global Rapid Influenza Diagnostic Tests market share include Quidel Corporation, Becton Dickinson and Company, Thermo Fisher Scientific, Abbott Laboratories, and F. Hoffmann-La Roche Ltd., among others. In 2024 and 2025, these market players undertook significant growth strategies such as new product launches—Quidel introduced an improved molecular RIDT platform in mid-2025 that reduced test time by 30%, enhancing market penetration. Abbott Laboratories expanded capacity in 2024 by opening a state-of-the-art manufacturing facility geared towards lateral flow immunoassays, boosting supply capabilities for the rising demand. Thermo Fisher Scientific entered several emerging markets through strategic partnerships, capturing new revenue streams amid shifting industry trends.
Key Winning Strategies Adopted by Key Players
Among the innovative growth strategies, Quidel Corporation’s 2025 launch of a cloud-connected molecular testing solution allowed real-time influenza surveillance data integration, aiding healthcare providers in epidemic preparedness—a unique approach not widely adopted in the industry that significantly improved test utilization and market visibility. Another impactful strategy was Becton Dickinson’s 2024 diversification into multiplex respiratory panels that cover influenza as well as COVID-19 and RSV, enabling bundled diagnostics with greater clinical value and higher revenue potential. Lastly, Roche’s investment in AI-driven diagnostic interpretation software since late 2024 enabled faster result analysis and reduced manual errors, enhancing overall user experience and reinforcing market leadership.
FAQs
Q1: Who are the dominant players in the Global Rapid Influenza Diagnostic Tests Market?
The dominant market players include Quidel Corporation, Becton Dickinson and Company, Thermo Fisher Scientific, Abbott Laboratories, and F. Hoffmann-La Roche Ltd., who lead with innovation and capacity expansions.
Q2: What will be the size of the Global Rapid Influenza Diagnostic Tests Market in the coming years?
The market size is forecasted to grow from USD 1.51 billion in 2025 to USD 2.60 billion by 2032, at a CAGR of 8.1%, reflecting robust market growth and expanding industry share.
Q3: Which end-user segment presents the largest growth opportunity?
Hospitals remain the largest end users due to high testing volumes, while diagnostic laboratories are rapidly adopting molecular RIDTs, indicating substantial growth opportunities in clinical and outpatient settings.
Q4: How will market development trends evolve over the next five years?
Market trends indicate increased integration of multiplex and molecular testing technologies, enhanced point-of-care diagnostics, and growing investment in digital connectivity for influenza surveillance.
Q5: What are the major challenges faced by the Global Rapid Influenza Diagnostic Tests Market?
Key market challenges include variability in test sensitivity, reimbursement constraints in some regions, and the need to balance cost-effectiveness with technological advancements.
Q6: What go-to-market strategies are commonly adopted in the Global Rapid Influenza Diagnostic Tests Market?
Common strategies include product innovation focusing on speed and accuracy, capacity expansions to meet growing demand, entry into emerging markets, and collaborations for technology integration.
‣ Get More Insights On: Global Rapid Influenza Diagnostic Tests Market
‣ Get This Report In Japanese Language: インフルエンザ迅速診断検査の世界市場
‣ Get This Report In Korean Language: 글로벌급속인플루엔자진단테스트시장
‣ Read More Related Articles: The Growing Viral Clearance Testing: Evolution of Regulatory Standards Drives Demand
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
